Hong Kong-listed WuXi Biologics’ proposed spin-off and Hong Kong listing of shares in subsidiary WuXi XDC has moved into pre-marketing, according to reports. In June, WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced the proposed spin-off and separate listing of its subsidiary WuXi XDC on the Main Board of the Hong Kong Stock…
Credit: Source link